MOH Stock Analysis: Molina Healthcare | NYSE
Healthcare Plans | NYSE, USA | Market Cap: 10.211m USD | 12M Return: 26% | US60855R1005 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 248M
EPS Trend: -72.2%
Qual. Beats: 0
Rev. Trend: 96.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Molina Healthcare, Inc. (NYSE: MOH) is a managed healthcare company that provides services to low-income families and individuals in the United States, primarily through government-sponsored programs including Medicaid and Medicare, as well as state insurance marketplaces established under the Affordable Care Act. The company operates through four reporting segments: Medicaid, Medicare, Marketplace, and Other. Founded in 1980 and headquartered in Long Beach, California, Molina has been publicly traded since its 2003 IPO and is classified as a large-cap stock within the GICS Managed Health Care sub-industry.
As a participant in the U.S. managed care sector, Molina operates primarily as a government contractor, receiving capitated payments to provide healthcare coverage to enrollees in state-administered Medicaid programs, dual-eligible beneficiaries, and ACA marketplace consumers. The managed health care model relies on coordinating care through contracted provider networks to manage costs and improve health outcomes for enrolled populations.
- Medicaid redeterminations cut enrollment and pressure revenue growth
- State contract RFP wins and losses drive membership expansion
- Medicare Advantage medical cost trends pressure segment margins
| Net Income: -7.00m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.94 > 1.0 |
| NWC/Revenue: 11.74% < 20% (prev 12.06%; Δ -0.32% < -1%) |
| CFO/TA 0.02 > 3% & CFO 365.0m > Net Income -7.00m |
| Net Debt (-4.78b) to EBITDA (371.0m): -12.88 < 3 |
| Current Ratio: 1.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.3m) vs 12m ago -5.52% < -2% |
| Gross Margin: 12.22% > 18% (prev 10.94%; Δ 1.28% > 0.5%) |
| Asset Turnover: 276.4% > 50% (prev 267.8%; Δ 8.60% > 0%) |
| Interest Coverage Ratio: 0.97 > 6 (EBIT TTM 203.0m / Interest Expense TTM 209.0m) |
| A: 0.33 (Total Current Assets 12.9b - Total Current Liabilities 7.70b) / Total Assets 16.0b |
| B: 0.23 (Retained Earnings 3.68b / Total Assets 16.0b) |
| C: 0.01 (EBIT TTM 203.0m / Avg Total Assets 16.1b) |
| D: 0.35 (Book Value of Equity 4.17b / Total Liabilities 11.8b) |
| Altman-Z'' = 3.35 = A |
| DSRI: 0.88 (Receivables 3.48b/3.87b, Revenue 44.5b/43.4b) |
| GMI: 0.89 (GM 10.94% / 12.22%) |
| AQI: 1.00 (AQ_t 0.17 / AQ_t-1 0.17) |
| SGI: 1.03 (Revenue 44.5b / 43.4b) |
| TATA: -0.02 (NI -7.00m - CFO 365.0m) / TA 16.0b) |
| Beneish M = -3.20 (Cap -4..+1) = AA |
As of August 07, 2026, the stock is trading at USD 191.88 with a total of 561,735 shares traded. Over the past week, the price has changed by -1.45%, over one month by -15.73%, over three months by -2.82% and over the past year by +25.98%.
Current recommended Stop Loss: 180.80 (which is 5.8% or 1.2 ATR below the current price).
Molina Healthcare has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold MOH.
- StrongBuy: 6
- Buy: 1
- Hold: 8
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 209.1 | 9% |
P/E Trailing = 1222.625
P/E Forward = 37.037
P/S = 0.2404
P/B = 2.4482
P/EG = 1.7394
Revenue TTM = 44.5b USD
EBIT TTM = 203.0m USD
EBITDA TTM = 371.0m USD
Long Term Debt = 3.77b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 4.14b USD (from shortLongTermDebtTotal, last quarter) + Leases 184.0m
Net Debt = -4.78b USD (calculated: Debt 4.14b - CCE 8.91b)
Enterprise Value = 5.43b USD (10.2b + Debt 4.14b - CCE 8.91b)
Interest Coverage Ratio = 0.97 (Ebit TTM 203.0m / Interest Expense TTM 209.0m)
EV/FCF = 20.05x (Enterprise Value 5.43b / FCF TTM 271.0m)
FCF Yield = 4.99% (FCF TTM 271.0m / Enterprise Value 5.43b)
FCF Margin = 0.61% (FCF TTM 271.0m / Revenue TTM 44.5b)
Net Margin = -0.02% (Net Income TTM -7.00m / Revenue TTM 44.5b)
Gross Margin = 12.22% ((Revenue TTM 44.5b - Cost of Revenue TTM 39.1b) / Revenue TTM)
Gross Margin QoQ = 8.54% (prev 9.47%)
Tobins Q-Ratio = 0.34 (Enterprise Value 5.43b / Total Assets 16.0b)
Interest Expense / Debt = 5.05% (Interest Expense 209.0m / Debt 4.14b)
Taxrate = 34.07% (31.0m / 91.0m)
NOPAT = 133.8m (EBIT 203.0m * (1 - 34.07%))
Current Ratio = 1.68 (Total Current Assets 12.9b / Total Current Liabilities 7.70b)
Debt / Equity = 0.99 (Debt 4.14b / totalStockholderEquity, last quarter 4.17b)
Debt / EBITDA = -12.88 (Net Debt -4.78b / EBITDA 371.0m)
Debt / FCF = -17.63 (Net Debt -4.78b / FCF TTM 271.0m)
Total Stockholder Equity = 4.13b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.04% (Net Income -7.00m / Total Assets 16.0b)
RoE = -0.17% (Net Income TTM -7.00m / Total Stockholder Equity 4.13b)
RoCE = 2.57% (EBIT 203.0m / Capital Employed (Equity 4.13b + L.T.Debt 3.77b))
RoIC = 2.20% (NOPAT 133.8m / Invested Capital 6.08b)
WACC = 5.01% (E(10.2b)/V(14.3b) * Re(5.69%) + D(4.14b)/V(14.3b) * Rd(5.05%) * (1-Tc(0.34)))
Discount Rate = 5.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.94 | Cagr: -5.53%
[DCF] Terminal Value 73.10% ; FCFF base≈333.4m ; Y1≈292.4m ; Y5≈236.2m
[DCF] Fair Price = 164.2 (EV 3.79b - Net Debt -4.78b = Equity 8.57b / Shares 52.2m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -72.17 | EPS CAGR: -40.04% | SUE: 0.11 | # QB: 0
Revenue Correlation: 96.40 | Revenue CAGR: 12.78% | SUE: 0.37 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.83 | Chg30d=-33.32% | Revisions=-50% | Analysts=18
EPS current Year (2026-12-31): EPS=5.24 | Chg30d=+1.73% | Revisions=+17% | GrowthEPS=-52.5% | GrowthRev=-2.2%
EPS next Year (2027-12-31): EPS=8.55 | Chg30d=+5.92% | Revisions=+25% | GrowthEPS=+190.3% | GrowthRev=+8.2%
[Analyst] Revisions Ratio: -10% (up=3, down=4)